Azacitidine-associated hyperthermia and interstitial pneumonitis in a patient with myelodysplasia syndrome

Pharmacotherapy

Volumn 27, Issue 12 I, 2007, Pages 1759-1762

  Hueser, Christopher N ^a   Patel, Anjali J ^a  

^a SAINT LOUIS UNIVERSITY HOSPITAL   (United States)

Author keywords

Acute respiratory distress syndrome; ARDS; Azacitidine; Hyperthermia; Interstitial pneumonitis; MDS; Myelodysplastic syndrome

Indexed keywords

AMPHETAMINE; ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; ATROPINE; AZACITIDINE; BENZATROPINE; COCAINE; CORTICOSTEROID; HALOPERIDOL; METHYLPREDNISOLONE; MONOAMINE OXIDASE INHIBITOR; PARACETAMOL; PHENOTHIAZINE; SUXAMETHONIUM;

ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; ANEMIA; ARTICLE; BLOOD CULTURE; BRONCHOSCOPY; CASE REPORT; CLINICAL FEATURE; COMA; COMPUTER ASSISTED TOMOGRAPHY; CONSTIPATION; DIARRHEA; DISEASE COURSE; DISEASE SEVERITY; DNA METHYLATION; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; ECCHYMOSIS; FATIGUE; FEMALE; FEVER; FIBROSING ALVEOLITIS; HUMAN; HYPERTHERMIA; INJECTION SITE REACTION; INTERSTITIAL PNEUMONIA; KIDNEY FAILURE; LEUKOPENIA; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUROTRANSMISSION; NEUTROPENIA; PETECHIA; PROTEIN PHOSPHORYLATION; RIGOR; SEROTONIN SYNDROME; THERMOGENESIS; THERMOREGULATION; THROMBOCYTOPENIA; VOMITING;

ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; FEMALE; FEVER; GLUCOCORTICOIDS; HUMANS; LUNG DISEASES, INTERSTITIAL; METHYLPREDNISOLONE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PROBABILITY; RESPIRATORY DISTRESS SYNDROME, ADULT;

EID: 36849016816     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.27.12.1759     Document Type: Article

References (16)

1. Sullivan M, Hahn K, Kolesar JM. Azacitidine: a novel agent for myelodysplastic syndromes. Am J Health Syst Pharm 2005;62:1567-73.
2. Adams CD, Szumita PM, Baroletti SA, Lilly CM. Azacitidine-induced interstitial and alveolar fibrosis in a patient with myelodysplastic syndrome. Pharmacotherapy 2005;25:765-8.
3. Sudan N, Rosetti JM, Shadduck RK, et al. Treatment of acute myelogenous leukemia with outpatient azacitidine. Cancer 2006;107:1839-43.
4. Gryn J, Zeigler ZR, Shadduck RK, et al. Treatment of myelodysplastic syndromes with 5-azacytidine. Leukemia Res 2002;26:893-7.
5. Leone G, Voso MT, Teofili L, Lubbert M. Inhibitors of DNA methylation in the treatment of hematological malignancies and MDS. Clin Immunol 2003;109:89-102.
6. Silverman LR. Targeting hypomethylation of DNA to achieve cellular differentiation in myelodysplastic syndromes (MDS). Oncologist 2001;6:8-14.
7. Kuykendall JR. 5-Azacytidine and decitabine monotherapies of myelodysplastic disorders. Ann Pharmacother 2005;39:1700-9.
8. MD Consult Drugs. Azacitidine, June 2007. Available from http://www.mdconsult.com. Accessed June 10, 2007.
9. Rusyniak D, Sprague J. Toxin-induced hyperthermic syndromes. Med Clin North Am 2005;89:1277-96.
10. Halloran L, Bernard D. Management of drug-induced hyperthermia. Curr Opin Ped 2004;16:211-15.
11. Chan T, Evans S, Clark R. Drug-induced hyperthermia. Crit Care Clin 1997;13:785-808.
12. Beaver K, Gavin T. Treatment of acute anticholinergic poisoning with physostigmine. Am J Emerg Med 1998;16:505-7.
13. Krause T, Gerbershagen MU, Fiege M, Weibhorn R, Wappler F. Dantrolene: a review of its pharmacology, therapeutic use and new developments. Anesthesia 2004;59:364-73.
14. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;80(2):286-91.
15. Meduri GU, Headley AS, Golden E, et al. Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome: a randomized controlled trial. JAMA 1998;280:150-65.
16. Meduri GU, Tolley EA, Chrousos GP, Stentz F. Prolonged methylprednisolone treatment suppresses inflammation in patients with unresolving acute respiratory distress syndrome: evidence for inadequate endogenous glucocorticoid secretion and inflammation-induced immune cell resistance to glucocorticoids. Am J Respir Crit Care Med 2002;165:983-91.